Two Co(Ⅱ)and Ni(Ⅱ)complexes were synthesized by synergistic coordination of 3,3-diphenylpropionic acid(HDPA)and 2,2′-bipyridylamine(PAm).The structures of complexes[Co(DPA)2(PAm)]·2H2O(1)and[Ni(DPA)2(...Two Co(Ⅱ)and Ni(Ⅱ)complexes were synthesized by synergistic coordination of 3,3-diphenylpropionic acid(HDPA)and 2,2′-bipyridylamine(PAm).The structures of complexes[Co(DPA)2(PAm)]·2H2O(1)and[Ni(DPA)2(PAm)]·2H2O(2)were determined by single-crystal X-ray diffraction,IR spectroscopy,and powder X-ray diffraction.Hirshfeld surface analysis provided quantitative insights into the intermolecular interactions within the complexes,while molecular docking studies elucidated their binding modes and affinities toward urease.Furthermore,the biological activities of both complexes were systematically evaluated through a range of assays,including DNA binding,urease inhibition,antibacterial activity,and in vitro cytotoxicity against cancer cells.Both complexes exhibited binding affinity for DNA and displayed notable urease inhibitory activity.Under in vitro conditions,both complexes showed appreciable cytotoxicity toward HepG2 cells with efficacy comparable to clinically used platinumbased anticancer agents.CCDC:2479943,1;2479944,2.展开更多
目的:系统评价间充质干细胞(MSC)治疗炎症性自身免疫疾病[包括克罗恩病(CD)、类风湿关节炎(RA)、狼疮性肾炎(LN)和多发性硬化症(MS)]的临床有效性与安全性。方法:系统检索PubMed、Web of Science、Embase、中国知网、万方和维普数据库(...目的:系统评价间充质干细胞(MSC)治疗炎症性自身免疫疾病[包括克罗恩病(CD)、类风湿关节炎(RA)、狼疮性肾炎(LN)和多发性硬化症(MS)]的临床有效性与安全性。方法:系统检索PubMed、Web of Science、Embase、中国知网、万方和维普数据库(截至2025年3月),纳入随机对照试验(RCT)及前瞻性单臂研究,采用随机效应模型进行Meta分析。结果:最终纳入19篇研究(15篇RCT、4篇单臂研究)。Meta分析显示,MSC治疗整体临床有效性优于对照组(RR=1.43,95%CI:0.94~2.18),但未达统计学显著性,研究间异质性显著(I²=74.2%)。安全性方面,MSC治疗组一般不良反应发生率(RR=1.04,95%CI:0.94~1.15)及严重不良事件发生率(RR=1.20,95%CI:0.85~1.70)与对照组无显著差异。亚组分析提示,MSC治疗对CD疗效明确(RR=1.49,95%CI:1.21~1.84),其他疾病疗效不确定。结论:MSC治疗炎症性自身免疫疾病显示一定临床潜力,安全性良好,但总体疗效尚需更严格、更大规模的RCT进一步确认。展开更多
摘要Two Co(Ⅱ)and Ni(Ⅱ)complexes were synthesized by synergistic coordination of 3,3-diphenylpropionic acid(HDPA)and 2,2′-bipyridylamine(PAm).The structures of complexes[Co(DPA)2(PAm)]·2H2O(1)and[Ni(DPA)2(PAm)]·2H2O(2)were determined by single-crystal X-ray diffraction,IR spectroscopy,and powder X-ray diffraction.Hirshfeld surface analysis provided quantitative insights into the intermolecular interactions within the complexes,while molecular docking studies elucidated their binding modes and affinities toward urease.Furthermore,the biological activities of both complexes were systematically evaluated through a range of assays,including DNA binding,urease inhibition,antibacterial activity,and in vitro cytotoxicity against cancer cells.Both complexes exhibited binding affinity for DNA and displayed notable urease inhibitory activity.Under in vitro conditions,both complexes showed appreciable cytotoxicity toward HepG2 cells with efficacy comparable to clinically used platinumbased anticancer agents.CCDC:2479943,1;2479944,2.
摘要目的:系统评价间充质干细胞(MSC)治疗炎症性自身免疫疾病[包括克罗恩病(CD)、类风湿关节炎(RA)、狼疮性肾炎(LN)和多发性硬化症(MS)]的临床有效性与安全性。方法:系统检索PubMed、Web of Science、Embase、中国知网、万方和维普数据库(截至2025年3月),纳入随机对照试验(RCT)及前瞻性单臂研究,采用随机效应模型进行Meta分析。结果:最终纳入19篇研究(15篇RCT、4篇单臂研究)。Meta分析显示,MSC治疗整体临床有效性优于对照组(RR=1.43,95%CI:0.94~2.18),但未达统计学显著性,研究间异质性显著(I²=74.2%)。安全性方面,MSC治疗组一般不良反应发生率(RR=1.04,95%CI:0.94~1.15)及严重不良事件发生率(RR=1.20,95%CI:0.85~1.70)与对照组无显著差异。亚组分析提示,MSC治疗对CD疗效明确(RR=1.49,95%CI:1.21~1.84),其他疾病疗效不确定。结论:MSC治疗炎症性自身免疫疾病显示一定临床潜力,安全性良好,但总体疗效尚需更严格、更大规模的RCT进一步确认。